Patents by Inventor JOHANNA KOLLN

JOHANNA KOLLN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Complement depletion using recombinant human C-3 derivatives
    Patent number: 8119769
    Abstract: The invention provides isolated polypeptides having complement-modulating activity. Specifically, the invention resides in the provision of isolated polypeptides having complement depleting properties, i.e. that effect an efficient consumption of complement in human serum. The current invention thus provides human C3 derivatives that are capable of forming C3 convertases exerting an extended CVF, Bb-like half-life of up several hours, compared to 1.5 minutes of the naturally occurring C3 convertases, thus escaping the physiological degradation mechanisms.
    Type: Grant
    Filed: April 23, 2009
    Date of Patent: February 21, 2012
    Assignee: PLS Design, GmbH
    Inventors: Johanna Kölln, Edzard Spillner, Reinhard Bredehorst
  • COMPLEMENT DEPLETION USING RECOMBINANT HUMAN C-3 DERIVATIVES
    Publication number: 20090270324
    Abstract: The invention provides isolated polypeptides having complement-modulating activity. Specifically, the invention resides in the provision of isolated polypeptides having complement depleting properties, i.e. that effect an efficient consumption of complement in human serum. The current invention thus provides human C3 derivatives that are capable of forming C3 convertases exerting an extended CVF, Bb-like half-life of up several hours, compared to 1.5 minutes of the naturally occurring C3 convertases, thus escaping the physiological degradation mechanisms.
    Type: Application
    Filed: April 23, 2009
    Publication date: October 29, 2009
    Inventors: JOHANNA KOLLN, EDZARD SPILLNER, REINHARD BREDEHORST
  • Complement depletion using recombinant human C3-derivatives
    Patent number: 7553931
    Abstract: The invention provides isolated polypeptides having complement-modulating activity. Specifically, the invention resides in the provision of isolated polypeptides having complement-depleting properties, i.e. that effect an efficient consumption of complement in human serum. The current invention thus provides human C3-derivatives that are capable of forming C3-convertases exerting an extended CVF, Bb-like half-life of up several hours, compared to 1.5 minutes of the naturally occurring C3-convertases, thus escaping the physiological degradation mechanisms.
    Type: Grant
    Filed: July 2, 2004
    Date of Patent: June 30, 2009
    Assignee: PLS-Design GmbH
    Inventors: Johanna Kölln, Edzard Spillner, Reinhard Bredehorst
  • Complement depletion using recombinant human C3-derivatives
    Publication number: 20050079585
    Abstract: The invention provides isolated polypeptides having complement-modulating activity. Specifically, the invention resides in the provision of isolated polypeptides having complement-depleting properties, i.e. that effect an efficient consumption of complement in human serum. The current invention thus provides human C-3 derivatives that are capable of forming C3convertases exerting an extended CVF,Bb-like half-life of up several hours, compared to 1.5 minutes of the naturally occurring C3convertases, thus escaping the physiological degradation mechanisms.
    Type: Application
    Filed: July 2, 2004
    Publication date: April 14, 2005
    Inventors: Johanna Kolln, Edzard Spillner, Reinhard Bredehorst